MX2018002435A - Sales de 1- (4- (2- ((1- (3,4-difluorofenil) -1h-pirazol-3-il) metoxi) etil) piperazin-1-il) etanona. - Google Patents
Sales de 1- (4- (2- ((1- (3,4-difluorofenil) -1h-pirazol-3-il) metoxi) etil) piperazin-1-il) etanona.Info
- Publication number
- MX2018002435A MX2018002435A MX2018002435A MX2018002435A MX2018002435A MX 2018002435 A MX2018002435 A MX 2018002435A MX 2018002435 A MX2018002435 A MX 2018002435A MX 2018002435 A MX2018002435 A MX 2018002435A MX 2018002435 A MX2018002435 A MX 2018002435A
- Authority
- MX
- Mexico
- Prior art keywords
- ethanone
- piperazin
- difluorophenyl
- pyrazol
- methoxy
- Prior art date
Links
- COKUNRYWXTVUAH-UHFFFAOYSA-N 1-[4-[2-[[1-(3,4-difluorophenyl)pyrazol-3-yl]methoxy]ethyl]piperazin-1-yl]ethanone Chemical class C1CN(C(=O)C)CCN1CCOCC1=NN(C=2C=C(F)C(F)=CC=2)C=C1 COKUNRYWXTVUAH-UHFFFAOYSA-N 0.000 title abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108010085082 sigma receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a sales de 1-(4-(2-((1-(3,4-diflu orofenil)-1H-pirazol-3-il)metoxi)etil)piperazin-1-il)etanona, específicamente a las clorhidrato y maleato, a composiciones farmacéuticas que las comprenden y a su uso en terapia y/o profilaxis de enfermedades asociadas con el receptor sigma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382436 | 2015-09-02 | ||
PCT/EP2016/070604 WO2017037166A1 (en) | 2015-09-02 | 2016-09-01 | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018002435A true MX2018002435A (es) | 2018-06-15 |
Family
ID=54106287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002435A MX2018002435A (es) | 2015-09-02 | 2016-09-01 | Sales de 1- (4- (2- ((1- (3,4-difluorofenil) -1h-pirazol-3-il) metoxi) etil) piperazin-1-il) etanona. |
Country Status (18)
Country | Link |
---|---|
US (1) | US10640468B2 (es) |
EP (1) | EP3344620B1 (es) |
JP (1) | JP6893916B2 (es) |
KR (1) | KR20180048923A (es) |
CN (1) | CN108026078A (es) |
AR (1) | AR105888A1 (es) |
AU (1) | AU2016315396B2 (es) |
CA (1) | CA2997359A1 (es) |
CO (1) | CO2018002429A2 (es) |
EC (1) | ECSP18015275A (es) |
IL (1) | IL257671A (es) |
MA (1) | MA43157A (es) |
MX (1) | MX2018002435A (es) |
RU (1) | RU2727974C2 (es) |
TW (1) | TWI752916B (es) |
UA (1) | UA124301C2 (es) |
WO (1) | WO2017037166A1 (es) |
ZA (1) | ZA201801544B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3336085A1 (en) | 2016-12-15 | 2018-06-20 | Laboratorios del Dr. Esteve S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10259406A1 (de) * | 2002-12-19 | 2004-07-01 | Cognis Deutschland Gmbh & Co. Kg | Milde Detergensgemische |
RU2417987C2 (ru) * | 2004-08-27 | 2011-05-10 | Лабораторьос Дель Др.Эстеве, С.А. | Ингибиторы сигма-рецептора |
WO2007094916A2 (en) * | 2006-01-19 | 2007-08-23 | Ambrx, Inc. | Non-natural amino acid polypeptides having modulated immunogenicity |
SI2503993T1 (sl) * | 2009-11-25 | 2016-10-28 | Laboratorios Del Dr. Esteve, S.A. | Hidrokloridna sol 4-(2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oksi) etil)morfolina |
EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
MA41177A (fr) * | 2014-12-15 | 2017-10-24 | Esteve Labor Dr | Utilisation de ligands des récepteurs sigma dans l'arthrose |
-
2016
- 2016-09-01 US US15/757,177 patent/US10640468B2/en not_active Expired - Fee Related
- 2016-09-01 JP JP2018510067A patent/JP6893916B2/ja active Active
- 2016-09-01 AU AU2016315396A patent/AU2016315396B2/en not_active Ceased
- 2016-09-01 RU RU2018111429A patent/RU2727974C2/ru active
- 2016-09-01 AR ARP160102670A patent/AR105888A1/es unknown
- 2016-09-01 CN CN201680051109.5A patent/CN108026078A/zh active Pending
- 2016-09-01 CA CA2997359A patent/CA2997359A1/en not_active Abandoned
- 2016-09-01 KR KR1020187009126A patent/KR20180048923A/ko not_active Application Discontinuation
- 2016-09-01 WO PCT/EP2016/070604 patent/WO2017037166A1/en active Application Filing
- 2016-09-01 UA UAA201803348A patent/UA124301C2/uk unknown
- 2016-09-01 TW TW105128276A patent/TWI752916B/zh active
- 2016-09-01 MA MA043157A patent/MA43157A/fr unknown
- 2016-09-01 MX MX2018002435A patent/MX2018002435A/es unknown
- 2016-09-01 EP EP16758212.1A patent/EP3344620B1/en active Active
-
2018
- 2018-02-21 IL IL257671A patent/IL257671A/en unknown
- 2018-02-27 EC ECIEPI201815275A patent/ECSP18015275A/es unknown
- 2018-03-02 CO CONC2018/0002429A patent/CO2018002429A2/es unknown
- 2018-03-06 ZA ZA2018/01544A patent/ZA201801544B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2997359A1 (en) | 2017-03-09 |
RU2018111429A (ru) | 2019-10-03 |
MA43157A (fr) | 2018-09-12 |
RU2018111429A3 (es) | 2020-02-04 |
US10640468B2 (en) | 2020-05-05 |
WO2017037166A1 (en) | 2017-03-09 |
EP3344620B1 (en) | 2022-10-26 |
KR20180048923A (ko) | 2018-05-10 |
IL257671A (en) | 2018-04-30 |
RU2727974C2 (ru) | 2020-07-28 |
ZA201801544B (en) | 2019-09-25 |
AU2016315396A1 (en) | 2018-03-22 |
ECSP18015275A (es) | 2018-04-30 |
CO2018002429A2 (es) | 2018-07-19 |
CN108026078A (zh) | 2018-05-11 |
EP3344620A1 (en) | 2018-07-11 |
JP2018526365A (ja) | 2018-09-13 |
UA124301C2 (uk) | 2021-08-25 |
JP6893916B2 (ja) | 2021-06-23 |
TWI752916B (zh) | 2022-01-21 |
AR105888A1 (es) | 2017-11-22 |
US20180251430A1 (en) | 2018-09-06 |
TW201713647A (zh) | 2017-04-16 |
AU2016315396B2 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500284A1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
PH12017500732A1 (en) | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine | |
MY186908A (en) | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof | |
MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
MX2018014700A (es) | Polimorfos de n-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoxime til)-1-({4-[(2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carbox amida y sales de los mismos. | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
TN2012000247A1 (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
TR201909353T4 (tr) | Multipl skleroz tedavisi. | |
PH12016502347A1 (en) | 1 -(cyclopent-2-en-1 -yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as cxcr2 inhibitors | |
MX2016013033A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados. | |
MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
PH12016500134A1 (en) | 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives | |
MX371102B (es) | Nuevos derivados de bencimidazol como agentes antihistaminicos. | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
MX2015012153A (es) | Inhibidores de la quinasa pirrolopirimidina cdk9. | |
MX2018002435A (es) | Sales de 1- (4- (2- ((1- (3,4-difluorofenil) -1h-pirazol-3-il) metoxi) etil) piperazin-1-il) etanona. | |
NZ738247A (en) | 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors | |
MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. | |
TH1601002081A (th) | รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต | |
EA202190043A2 (ru) | Замещенные гетероциклические производные как ингибиторы циклин-зависимой киназы (cdk) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: KONECRANES GLOBAL CORPORATION |